Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.60 |
| ▸ | F10 | P00742 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.55 |
| ▸ | PLAT | P00750 | 2/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | PLG | P00747 | 3/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057528 | 1.00 | F2 (0.60) | F2F10CA2TMPRSS6PLAT | |
| Piperidine SCHEMBL7370685 | 0.92 | F2 (0.53) | F2F10CA2TMPRSS6PLAT | |
| SCHEMBL9664068 | 0.90 | F10 (0.71) | F2F10TMPRSS6PLATPLAU | |
| SCHEMBL9710389 | 0.87 | F2 (0.70) | F2F10TMPRSS6ITGB3ITGA2B | |
| SCHEMBL7370481 | 0.87 | F2 (0.58) | F2F10TMPRSS6PLATKAT6A | |
| SCHEMBL9189122 | 0.86 | PLG (0.67) | F2F10PLAUPLG | |
| SCHEMBL29514928 | 0.86 | PLG (0.67) | F2F10PLAUPLG | |
| SCHEMBL29651383 | 0.86 | PLG (0.67) | F2F10PLAUPLG | |
| SCHEMBL872422 | 0.86 | PLG (0.67) | F2F10PLAUPLG | |
| SCHEMBL8144360 | 0.86 | PLG (0.67) | F2F10PLAUPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304815-A1 | Antimicrobial And Biological Active Polymer Composites And Related Methods, Materials and Devices | VACHON DAVID JOHN (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3190881-A1 | ANTIMICROBIAL AND BIOLOGICALLY ACTIVE POLYMER COMPOSITES AND RELATED METHODS, MATERIALS AND DEVICES | Iasis Molecular Sciences (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040529-A1 | ANTIMICROBIAL AND BIOLOGICALLY ACTIVE POLYMER COMPOSITES AND RELATED METHODS, MATERIALS AND DEVICES | IASIS MOLECULAR SCIENCES (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015071841-A1 | COMPLEXES OF DABIGATRAN AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Druggability Technologies Holdings Limited (IE) | 2015-05-21 | — | — | WO | disclosed |
| US-20100292183-A1 | TETRACYCLINE AND USES THEREOF | PLAXGEN, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2001079195-A2 | PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-5556941-A | ANTICOAGULANTS, THROMBIN INHIBITORS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1996-09-17 | — | — | US | disclosed |
| US-5250720-A | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5242904-A | Anticoagulant, antiinflammatory | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| US-5187157-A | Anticoagulant, antiinflammatory agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292183-A1 | TETRACYCLINE AND USES THEREOF | TET1, TET3, TNNT2 | F2 135/4885F10 471/4885CA2 2033/4885 |
| US-20170304815-A1 | Antimicrobial And Biological Active Polymer Composites And Related Methods, Materials and Devices | PHOSPHO1, PGLS, PUF60 | F2 1074/4885F10 118/4885CA2 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.